MedPath

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Phase 3
Completed
Conditions
Macular Degeneration
Interventions
Registration Number
NCT02462486
Lead Sponsor
Allergan
Brief Summary

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
949
Inclusion Criteria
  • Diagnosis of age-related macular degeneration in at least 1 eye
  • Best corrected visual acuity of 20/40 to 20/320 in the study eye
  • Best corrected visual acuity of 20/200 or better in the non-study eye
Exclusion Criteria
  • History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
  • Cataract or refractive surgery in the study eye within the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Abicipar Pegol 2 mg (2Q12)Sham ProcedureAbicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Abicipar Pegol 2 mg (2Q8)Sham ProcedureAbicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Abicipar Pegol 2 mg (2Q12)Abicipar PegolAbicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Ranibizumab (rQ4)RanibizumabRanibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
Abicipar Pegol 2 mg (2Q8)Abicipar PegolAbicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With Stable Vision at Week 52Baseline to Week 52

Stable vision was defined as vision loss of fewer than 15 letters in Best-corrected Visual Acuity (BCVA) from baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. Study eye was defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.

Secondary Outcome Measures
NameTimeMethod
Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 52Baseline to Week 52

BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Mixed-effect model for repeated measures (MMRM) analysis was used. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.

Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52Baseline to Week 52

CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye. MMRM analysis was used.

Percentage of Participants With BCVA Gain of More Than 15 Letters From Baseline in the Study Eye at Week 52Baseline to Week 52

BCVA is measured using an eye chart and is reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA gain of more than 15 letters are noted. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.

Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Week 52Baseline to Week 52

NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision. Overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye: eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.

Trial Locations

Locations (187)

Paducah Retinal Center

🇺🇸

Paducah, Kentucky, United States

Maculacare - New York

🇺🇸

New York, New York, United States

Retina Vitreous Surgeons of Central NY, PC

🇺🇸

Syracuse, New York, United States

Long Island Vitreoretinal Consultants

🇺🇸

Hauppauge, New York, United States

Charlotte Eye Ear Nose & Throat Associates, PA

🇺🇸

Charlotte, North Carolina, United States

Win Retina

🇺🇸

Arcadia, California, United States

Northwest Arkansas Retina Associates

🇺🇸

Springdale, Arkansas, United States

Retina Institute of California

🇺🇸

Arcadia, California, United States

Specialty Eye Care Medical Center, Inc.

🇺🇸

Glendale, California, United States

Retinal Diagnostic Center

🇺🇸

Campbell, California, United States

University of California at Irvine Gavin Herbert Eye Institute

🇺🇸

Irvine, California, United States

Retina Associates of Orange County

🇺🇸

Laguna Hills, California, United States

South Coast Retina Center

🇺🇸

Long Beach, California, United States

San Diego Retina Associates

🇺🇸

Oceanside, California, United States

California Eye Specialist Medical Group

🇺🇸

Pasadena, California, United States

Southern California Desert Retina Consultants

🇺🇸

Palm Desert, California, United States

Retina Consultants of Southern California

🇺🇸

Redlands, California, United States

Retina Consultants, San Diego

🇺🇸

Poway, California, United States

Kaiser Permanente Riverside Medical Center

🇺🇸

Riverside, California, United States

The Eye Associates

🇺🇸

Bradenton, Florida, United States

National Ophthalmic Research Institute

🇺🇸

Fort Myers, Florida, United States

Fort Lauderdale Eye Institute

🇺🇸

Plantation, Florida, United States

East Florida Eye Institute

🇺🇸

Stuart, Florida, United States

Sarasota Retina Institute

🇺🇸

Sarasota, Florida, United States

Center for Retina and Macular Disease

🇺🇸

Winter Haven, Florida, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Southeast Retina Center

🇺🇸

Augusta, Georgia, United States

Kovach Eye Institute

🇺🇸

Elmhurst, Illinois, United States

DuPage Medical Group

🇺🇸

Downers Grove, Illinois, United States

University Retina and Macula Associates

🇺🇸

Oak Forest, Illinois, United States

Wheaton Eye Clinic, Clinical Research Center, LLC

🇺🇸

Wheaton, Illinois, United States

Sabates Eye Centers

🇺🇸

Leawood, Kansas, United States

The Retina Care Center

🇺🇸

Baltimore, Maryland, United States

Cumberland Valley Retina Consultants, P.C.

🇺🇸

Hagerstown, Maryland, United States

Retina Specialists of Michigan

🇺🇸

Grand Rapids, Michigan, United States

Vitreo-Retinal Associates, Pc

🇺🇸

Worcester, Massachusetts, United States

Delaware Valley Retina Associates

🇺🇸

Lawrenceville, New Jersey, United States

Western Carolina Retinal Associates, PA

🇺🇸

Asheville, North Carolina, United States

Ohio State University

🇺🇸

Columbus, Ohio, United States

Retina Associates of Cleveland, Inc

🇺🇸

Beachwood, Ohio, United States

Pennsylvania Retina Specialists, P.C.

🇺🇸

Camp Hill, Pennsylvania, United States

Retina & Vitreous Center SO, PC

🇺🇸

Ashland, Oregon, United States

Midwest Retina, Inc.

🇺🇸

Dublin, Ohio, United States

The University of Texas Medical Branch

🇺🇸

Galveston, Texas, United States

Strategic Clinical Research Group, LLC

🇺🇸

Willow Park, Texas, United States

Retina and Vitreous of Texas

🇺🇸

Beaumont, Texas, United States

Premiere Retina Specialists

🇺🇸

Midland, Texas, United States

Retina Associates of South Texas, PA

🇺🇸

San Antonio, Texas, United States

Virginia Eye Consultants

🇺🇸

Norfolk, Virginia, United States

Wagner Macula and Retina Center

🇺🇸

Virginia Beach, Virginia, United States

Vitreoretinal Associates of Washington

🇺🇸

Bellevue, Washington, United States

Spokane Eye Clinical Research

🇺🇸

Spokane, Washington, United States

West Virginia University Eye Institute

🇺🇸

Morgantown, West Virginia, United States

Save Sight Institute, University of Sydney Eye Hospital

🇦🇺

Sydney, New South Wales, Australia

Sydney Retina Clinic and Day Surgery

🇦🇺

Sydney, New South Wales, Australia

Sydney West Retina

🇦🇺

Westmead, New South Wales, Australia

Centre for Eye Research Australia

🇦🇺

East Melbourne, Victoria, Australia

Specialist Eye Group

🇦🇺

Glen Waverley, Victoria, Australia

Lions Eye Institute

🇦🇺

Nedlands, Western Australia, Australia

Centro Brasileiro de Cirurgia de Olhos - CBCO

🇧🇷

Goiania, Goias, Brazil

Clinica de Olhos Dr. Suel Abujamra

🇧🇷

Sao Paulo, Brazil

Instistuto da Visao - Hospital de Olhos Ltda

🇧🇷

Belo Horizonte, Minas Gerais, Brazil

Canadian Centre for Advanced Eye Therapeutics Inc

🇨🇦

Mississauga, Ontario, Canada

Hospital Oftalmologico de Sorocaba

🇧🇷

Sorocaba, Sao Paulo, Brazil

Calgary Retina Consultants

🇨🇦

Calgary, Alberta, Canada

St Joseph's Health Care London - Ivey Eye Institute

🇨🇦

London, Ontario, Canada

University of Ottawa Eye Institute

🇨🇦

Ottawa, Ontario, Canada

Toronto Retina Institute

🇨🇦

Toronto, Ontario, Canada

Ganglion Medical Centre

🇭🇺

Pecs, Hungary

Budapest Retina Associates Kft.

🇭🇺

Budapest, Hungary

Clinica Oculistica- Dipartimento di Scienze Cliniche Universita di Milano

🇮🇹

Milan, Lombardy, Italy

Markusovszki Teaching Hospital

🇭🇺

Szombathely, Hungary

Eye Clinic - Fondazione IRCCS

🇮🇹

Milan, Lombardy, Italy

Azienda Ospedaliero-Universitaria Careggi - SOD Oculistica, Dipartimento di Chirurgia e Medicina Traslazionale

🇮🇹

Firenze, Tuscany, Italy

Ospedale Molinette

🇮🇹

Torino, Piedmont, Italy

Azienda Universitaria Ospedaliera Pisana, Ospedale "Nuovo S.Chiara" Cisanello

🇮🇹

Pisa, Tuscany, Italy

Japan Community Health Care Organization Chukyo Hospital

🇯🇵

Nagoya, Aichi, Japan

Nagoya University Hospital

🇯🇵

Nagoya, Aichi, Japan

Ogaki Tokushukai Hospital

🇯🇵

Ogaki, Gifu, Japan

Kameda Clinic

🇯🇵

Kamogawa, Chiba, Japan

Juntendo University Urayasu Hospital

🇯🇵

Urayasu, Chiba, Japan

Toho University Sakura Medical Center

🇯🇵

Sakura, Chiba, Japan

Kimura Eye And Internal Medicine Hospital

🇯🇵

Kure, Hiroshima, Japan

Hyogo Prefectural Amagasaki Hospital General Medical Center

🇯🇵

Amagasaki, Hyogo, Japan

Sapporo City General Hospital

🇯🇵

Sapporo, Hokkaido, Japan

Tokyo Medical University Ibaraki Medical Center

🇯🇵

Inashiki, Ibaraki, Japan

Mito Kyodo General Hospital

🇯🇵

Mito, Ibaraki, Japan

Otakeganka Tsukimino Clinic

🇯🇵

Yamato, Kanagawa, Japan

Kikuna Yuda Eye Clinic

🇯🇵

Kanagawa, Kanto, Japan

Mie University Hospital

🇯🇵

Tsu, Mie, Japan

Iida Municipal Hospital

🇯🇵

Iida, Nagano, Japan

Seirei Hamamatsu General Hospital

🇯🇵

Hamamatsu, Shizuoka, Japan

Takeuchi Eye Clinic

🇯🇵

Taito, Tokyo, Japan

Nihon University Hospital

🇯🇵

Chiyoda, Tokyo, Japan

Chofu Eye Clinic

🇯🇵

Chofu, Tokyo, Japan

Kyushu University Hospital

🇯🇵

Fukuoka, Japan

Fukushima Medical University Hospital

🇯🇵

Fukushima, Japan

Kokura Kinen Hospital

🇯🇵

Kitakyushu, Japan

Ideta Eye Hospital

🇯🇵

Kumamoto, Japan

The Japanese Red Cross Nagasaki Genbaku Hospital

🇯🇵

Nagasaki, Japan

Nara Medical University Hospital

🇯🇵

Nara, Japan

Medical Corporation Jinshikai Nishi Eye Hospital

🇯🇵

Osaka, Japan

Tane Memorial Eye Hospital

🇯🇵

Osaka, Japan

Tokyo Women's Medical University Hospital

🇯🇵

Tokyo, Japan

Elisabeth Hospital

🇳🇱

Tilburg, North Brabant, Netherlands

Leiden University Medical Center

🇳🇱

Leiden, South Holland, Netherlands

Macula D&T Eye Center

🇵🇪

San Isidro, Lima, Peru

Optimum Profesorskie Centrum Okulistyki

🇵🇱

Gdansk, Poland

Centrum Diagnostyki i Mikrochirurgii

🇵🇱

Olsztyn, Poland

Scientific Research Institute of Ocular Diseases of RAMS

🇷🇺

Moscow, Russian Federation

Uniwersytecki Szpital Kliniczny

🇵🇱

Wrocław, Poland

S. Fyodorov Eye Microsurgery Federal State Institution

🇷🇺

Moscow, Russian Federation

Dr Actons Privat Practice

🇿🇦

Cape Town, South Africa

Pasteur Medical Centre

🇿🇦

Bloemfontein, South Africa

Pretoria Eye Institute, Private Practice

🇿🇦

Pretoria, South Africa

Department of Ophthalmology Kaohsiung Veterans General Hospital

🇨🇳

Kaohsiung, Taiwan

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Chang Gung Medical Foundation, Linkou Branch

🇨🇳

Taoyuan, Taiwan

Shin Kong Wu Ho-Su Memorial Hospital

🇨🇳

Taipei, Taiwan

Ankara Uni Med Fac

🇹🇷

Ankara, Turkey

Royal Derby Hospital

🇬🇧

Derby, Derbyshire, United Kingdom

Dokuz Eylul Uni Med Fac

🇹🇷

Izmir, Turkey

Frimley Park Hospital

🇬🇧

Frimley, Camberley, United Kingdom

ESNEFT Essex County Hospital

🇬🇧

Colchester, Essex, United Kingdom

University Hospital Southampton

🇬🇧

Southampton, Hampshire, United Kingdom

Heart of England NHS Foundation Trust, Good Hope Hospital

🇬🇧

Sutton Coldfield, Staffordshire, United Kingdom

Royal Surrey Hospital

🇬🇧

Guildford, South East, United Kingdom

Bradford Royal Infirmary (BRI)

🇬🇧

Bradford, West Yorkshire, United Kingdom

Bristol Eye Hospital

🇬🇧

Bristol, United Kingdom

Barnet Hospital

🇬🇧

Barnet, United Kingdom

University Hospital Aintree

🇬🇧

Liverpool, United Kingdom

Moorfields Eye Hospital

🇬🇧

London, United Kingdom

Hospital of St. Cross

🇬🇧

Rugby, United Kingdom

City Hospitals Sunderland NHS

🇬🇧

Sunderland, United Kingdom

Barnet Royal Free Hospital

🇬🇧

London, United Kingdom

King's College Hospital

🇬🇧

London, United Kingdom

Retina Macula Specialists of Miami

🇺🇸

Miami, Florida, United States

MedEye Associates

🇺🇸

Miami, Florida, United States

Cincinnati Eye Institute

🇺🇸

Cincinnati, Ohio, United States

Academic Medical Center

🇳🇱

Amsterdam, North Holland, Netherlands

Oogziekenhuis Rotterdam

🇳🇱

Rotterdam, North Holland, Netherlands

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

Rigshospitalet-Glostrup

🇩🇰

Glostrup, Hovedstaden, Denmark

Odense University Hospital

🇩🇰

Odense, Syddanmark, Denmark

Barnet Dulaney Perkins Eye Center - Phoenix

🇺🇸

Phoenix, Arizona, United States

University of Utah, John Moran Eye Center

🇺🇸

Salt Lake City, Utah, United States

West Coast Retina Medical Group

🇺🇸

San Francisco, California, United States

Pacific Eye Associates

🇺🇸

San Francisco, California, United States

Eye Foundation Hospital

🇺🇸

Birmingham, Alabama, United States

Oregon Health Sciences University

🇺🇸

Portland, Oregon, United States

Ospedale Clinicizzato

🇮🇹

Chieti, Abruzzi, Italy

Clinica Oculistica, Ospedale Santa Maria della Misericordia

🇮🇹

Udine, Friuli-Venezia Giulia, Italy

IRCCS - Istuto di Recovero e Cura a Carattere Scientifico

🇮🇹

Verona, Vento, Italy

A.O.U. Policlinico Sant Orsola Malpighi Pad1, 4Piano, Studio Medici via Pelagio Palagi 9

🇮🇹

Bologna, Italy

Clinica Oculistica DINOGMI Universita di Genova

🇮🇹

Genova, Italy

IRCCS Ospedale San Raffaele

🇮🇹

Milano, Italy

Policlinico Agostino Gemelli

🇮🇹

Roma, Italy

Fondazione G.B. Bietti-IRCCS

🇮🇹

Roma, Italy

Oxford Eye Hospital, John Radcliffe Hospital

🇬🇧

Oxford, Headington, United Kingdom

Sheffield Teaching Hospitals

🇬🇧

Sheffield, Yorkshire, United Kingdom

Royal Victoria Infirmary

🇬🇧

Newcastle, United Kingdom

Instituto Da Visao UNIFESP EPM (Universidade Federal de Sao Paulo - Escola Paulista de Medicina)

🇧🇷

Sao Paulo, Brazil

Retina Vitreous Associates of Florida

🇺🇸

Tampa, Florida, United States

Retina Associate of Florida, P.A.

🇺🇸

Tampa, Florida, United States

Shiga University of Medical Science Hospital

🇯🇵

Otsu, Shiga, Japan

Aichi Medical University Hospital

🇯🇵

Nagakute, Aichi, Japan

Retinal Consultants of Arizona

🇺🇸

Gilbert, Arizona, United States

Magyar Honvedseg Egeszegugyi Kozpont

🇭🇺

Budapest, Hungary

Retina Center of New Jersey, LLC

🇺🇸

Bloomfield, New Jersey, United States

University Hospital of Wales

🇬🇧

Cardiff, Wales, United Kingdom

University of Szeged

🇭🇺

Szeged, Hungary

Tokyo Medical University Hachioji Medical Center

🇯🇵

Hachioji, Tokyo, Japan

Department of Ophthalmology National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Semmelweis University

🇭🇺

Budapest, Hungary

Bajcsy-Zsilinszky Hospital

🇭🇺

Budapest, Hungary

Retina Eye Hospital

🇵🇱

Warsaw, Poland

Szent Imre Teaching Hospital

🇭🇺

Budapest, Hungary

University of Debrecen, Medical Center

🇭🇺

Debrecen, Hungary

Musashi Dream Clinic

🇯🇵

Osaka, Japan

Klinika Okulistyczna Jasne Blonia

🇵🇱

Lodz, Poland

Black Hills Regional Eye Institute

🇺🇸

Rapid City, South Dakota, United States

Retinal Consultants Medical Group, Inc.

🇺🇸

Sacramento, California, United States

UC Davis Medical Center, Department of Ophthalmology

🇺🇸

Sacramento, California, United States

Austin Retina Associates

🇺🇸

Austin, Texas, United States

Retina Centers, PC

🇺🇸

Tucson, Arizona, United States

East Bay Retina Consultants, Inc.

🇺🇸

Oakland, California, United States

Royal Liverpool University Hospital

🇬🇧

Liverpool, North West England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath